Literature DB >> 8709137

3-[2-(N-phenylacetamide)]-1,5-benzodiazepines: orally active, binding selective CCK-A agonists.

T M Willson1, B R Henke, T M Momtahen, P L Myers, E E Sugg, R J Unwalla, D K Croom, R W Dougherty, M K Grizzle, M F Johnson, K L Queen, T J Rimele, J D Yingling, M K James.   

Abstract

A series of modifications were made to the C-3 substituent of the 1,5-benzodiazepine CCK-A agonist 1. Replacement of the inner urea NH and addition of a methyl group to generate a C-3 quaternary carbon resulted in acetamide 6, which showed CCK-A receptor binding selectivity and sub-micromolar agonist activity in vitro. Benzodiazepine 6 was active in an in vivo mouse gallbladder emptying assay and represents a novel orally active, binding selective CCK-A agonist.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8709137     DOI: 10.1021/jm960205b

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  4 in total

1.  Characterization of a novel nonpeptide vasopressin V(2)-agonist, OPC-51803, in cells transfected human vasopressin receptor subtypes.

Authors:  S Nakamura; Y Yamamura; S Itoh; T Hirano; K Tsujimae; M Aoyama; K Kondo; H Ogawa; T Shinohara; K Kan; Y Tanada; S Teramoto; T Sumida; S Nakayama; K Sekiguchi; T Kambe; G Tsujimoto; T Mori; M Tominaga
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

2.  Antidepressant/anxiolytic and anti-nociceptive effects of novel 2-substituted 1,4-benzodiazepine-2-ones.

Authors:  Harjit Singh; Jintana Sattayasai; Pornthip Lattmann; Yodchai Boonprakob; Eric Lattmann
Journal:  Sci Pharm       Date:  2010-05-17

3.  Ancient-modern concordance in Ayurvedic plants: some examples.

Authors:  S Dev
Journal:  Environ Health Perspect       Date:  1999-10       Impact factor: 9.031

4.  Development of novel bone targeting peptide-drug conjugate of 13-aminomethyl-15-thiomatrine for osteoporosis therapy.

Authors:  Jia Su; Chao Liu; Haohao Bai; Wei Cong; Hua Tang; Honggang Hu; Li Su; Shipeng He; Yong Wang
Journal:  RSC Adv       Date:  2021-12-20       Impact factor: 3.361

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.